Katherine R. Goetzinger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Katherine R. Goetzinger has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Anthony O. Odibo
Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri
10 shared publicationsAlison G. Cahill
Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri
9 shared publicationsGeorge A. Macones
Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri
9 shared publicationsDiana L. Gray
Department of Obstetrics and Gynecology, Washington University in St Louis, USA
2 shared publicationsJeffrey M. Dicke
Department of Obstetrics and Gynecology, Washington University in St Louis, USA
2 shared publicationsLinda Odibo
Department of Obstetrics and Gynecology, Washington University, St Louis, Missouri USA
2 shared publications
Latest Publications
- 4 April 2014
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 31 (12) , 1049-1056
Development and Validation of a Risk Factor Scoring System for First-Trimester Prediction of Preeclampsia
Objective The aim of this study was to develop a multiparameter risk-based scoring system for first-trimester prediction of preeclampsia and to validate this scoring system in our patient population. Study Design Secondary analysis of a prospective cohort of 1,200 patients presenting for first-trimester aneuploidy screening. Maternal serum pregnancy-associated plasma protein A (PAPP-A) levels were measured and bilateral uterine artery (UA) Doppler studies performed. Using the first half of the study population, a prediction model for preeclampsia was created. Test performance characteristics were used to determine the optimal score for predicting preeclampsia. This model was then validated in the second half of the population. Results Significant risk factors and their weighted scores derived from the prediction model were chronic hypertension (4), history of preeclampsia (3), pregestational diabetes (2), body mass index ≥ 30 kg/m2 (2), bilateral UA notching (1), and PAPP-A MoM < 10th percentile (1). The area under the curve (AUC) for the risk scoring system was 0.76 (95% confidence interval [CI], 0.69–0.83), and the optimal threshold for predicting preeclampsia was a total score of ≥ 6. This AUC did not differ significantly from the AUC observed in our validation cohort (AUC, 0.78 [95% CI, 0.69–0.86]; p = 0.75]. Conclusion Our proposed risk factor scoring system demonstrates modest accuracy but excellent reproducibility for first-trimester prediction of preeclampsia.
- 4 April 2014
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 31 (12) , 1049-1056
Development and Validation of a Risk Factor Scoring System for First-Trimester Prediction of Preeclampsia
Objective The aim of this study was to develop a multiparameter risk-based scoring system for first-trimester prediction of preeclampsia and to validate this scoring system in our patient population. Study Design Secondary analysis of a prospective cohort of 1,200 patients presenting for first-trimester aneuploidy screening. Maternal serum pregnancy-associated plasma protein A (PAPP-A) levels were measured and bilateral uterine artery (UA) Doppler studies performed. Using the first half of the study population, a prediction model for preeclampsia was created. Test performance characteristics were used to determine the optimal score for predicting preeclampsia. This model was then validated in the second half of the population. Results Significant risk factors and their weighted scores derived from the prediction model were chronic hypertension (4), history of preeclampsia (3), pregestational diabetes (2), body mass index ≥ 30 kg/m2 (2), bilateral UA notching (1), and PAPP-A MoM < 10th percentile (1). The area under the curve (AUC) for the risk scoring system was 0.76 (95% confidence interval [CI], 0.69–0.83), and the optimal threshold for predicting preeclampsia was a total score of ≥ 6. This AUC did not differ significantly from the AUC observed in our validation cohort (AUC, 0.78 [95% CI, 0.69–0.86]; p = 0.75]. Conclusion Our proposed risk factor scoring system demonstrates modest accuracy but excellent reproducibility for first-trimester prediction of preeclampsia.
- Open Access
- 1 September 2013
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 32 (9) , 1593-1600
Efficiency of First‐Trimester Uterine Artery Doppler, A‐Disintegrin and Metalloprotease 12, Pregnancy‐Associated Plasma Protein A, and Maternal Characteristics in the Prediction of Preeclampsia
Objectives: The purpose of this study was to estimate the efficiency of first‐trimester uterine artery Doppler, A‐disintegrin and metalloprotease 12 (ADAM12), pregnancy‐associated plasma protein A (PAPP‐A), and maternal characteristics in the prediction of preeclampsia.Methods: We conducted a prospective cohort study of patients presenting for first‐trimester aneuploidy screening between 11 and 14 weeks' gestation. Maternal serum ADAM12 and PAPP‐A levels were measured by an immunoassay, and mean uterine artery Doppler pulsatility indices were calculated. Outcomes of interest included preeclampsia, early preeclampsia (defined as requiring delivery at U statistics.Results: Among 578 patients with complete outcome data, there were 54 cases of preeclampsia (9.3%) and 13 cases of early preeclampsia (2.2%). Median ADAM12 levels were significantly lower in patients who developed preeclampsia compared to those who did not (0.81 versus 1.01 MoM; P = .04). For a fixed false‐positive rate of 10%, ADAM12, PAPP‐A, and uterine artery Doppler parameters in combination with maternal characteristics identified 50%, 48%, and 52% of patients who developed preeclampsia, respectively. Combining these first‐trimester parameters did not improve the predictive efficiency of the models.Conclusions: First‐trimester ADAM12, PAPP‐A, and uterine artery Doppler characteristics are not sufficiently predictive of preeclampsia. Combinations of these parameters do not further improve their screening efficiency.
- 1 September 2013
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 32 (9) , 1593-1600
Open AccessEfficiency of First‐Trimester Uterine Artery Doppler, A‐Disintegrin and Metalloprotease 12, Pregnancy‐Associated Plasma Protein A, and Maternal Characteristics in the Prediction of Preeclampsia
Objectives: The purpose of this study was to estimate the efficiency of first‐trimester uterine artery Doppler, A‐disintegrin and metalloprotease 12 (ADAM12), pregnancy‐associated plasma protein A (PAPP‐A), and maternal characteristics in the prediction of preeclampsia.Methods: We conducted a prospective cohort study of patients presenting for first‐trimester aneuploidy screening between 11 and 14 weeks' gestation. Maternal serum ADAM12 and PAPP‐A levels were measured by an immunoassay, and mean uterine artery Doppler pulsatility indices were calculated. Outcomes of interest included preeclampsia, early preeclampsia (defined as requiring delivery at U statistics.Results: Among 578 patients with complete outcome data, there were 54 cases of preeclampsia (9.3%) and 13 cases of early preeclampsia (2.2%). Median ADAM12 levels were significantly lower in patients who developed preeclampsia compared to those who did not (0.81 versus 1.01 MoM; P = .04). For a fixed false‐positive rate of 10%, ADAM12, PAPP‐A, and uterine artery Doppler parameters in combination with maternal characteristics identified 50%, 48%, and 52% of patients who developed preeclampsia, respectively. Combining these first‐trimester parameters did not improve the predictive efficiency of the models.Conclusions: First‐trimester ADAM12, PAPP‐A, and uterine artery Doppler characteristics are not sufficiently predictive of preeclampsia. Combinations of these parameters do not further improve their screening efficiency.
- Open Access
- 25 July 2013
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 43 (4) , 420-425
Sonographic predictors of postnatal bowel atresia in fetal gastroschisis
Objectives: To estimate the association between antenatal bowel dilation and postnatal small‐bowel atresia in fetal gastroschisis and to establish a threshold at which the risk of adverse neonatal outcome increases.Methods: This was a retrospective cohort study of singleton gestations with an antenatal diagnosis of gastroschisis seen in our ultrasound unit from 2001 to 2010. We reviewed stored images from the last ultrasound examination before delivery, blinded to postnatal diagnoses and outcomes. Fetal intra‐ and extra‐abdominal bowel dilation (IABD and EABD, respectively) and bowel‐wall thickness were measured. Previously published definitions of bowel dilation, including > 6, > 10, > 14 and > 18 mm, were evaluated for association with the primary outcome of bowel atresia. The optimal threshold to define fetal bowel dilation was determined by evaluating the significance of association as well as test performance characteristics.Results: Of 109 consecutive patients with fetal gastroschisis, there were four cases of intrauterine fetal demise and three neonatal deaths. Of the 94 live births with complete outcome data, 39 (41.5%) had measurable IABD. There were 14 (14.9%) cases of bowel atresia. Using a threshold of > 14 mm, IABD was significantly associated with an increased risk for bowel atresia (relative risk, 3.1 (95% CI, 1.2–8.2)) with a sensitivity of 57.1%, specificity of 75.0%, positive predictive value of 28.6% and negative predictive value of 90.9%. IABD > 14 mm was also associated with a significantly longer stay in neonatal intensive care unit. There was no significant association between EABD and bowel atresia at any of the thresholds evaluated.Conclusion: IABD > 14 mm is associated with an increased risk for postnatal bowel atresia in fetal gastroschisis. This finding may be useful in counseling patients regarding the anticipated postnatal course for their neonate. Copyright © 2013 ISUOG. Published by John Wiley & Sons Ltd.
- 25 July 2013
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 43 (4) , 420-425
Open AccessSonographic predictors of postnatal bowel atresia in fetal gastroschisis
Objectives: To estimate the association between antenatal bowel dilation and postnatal small‐bowel atresia in fetal gastroschisis and to establish a threshold at which the risk of adverse neonatal outcome increases.Methods: This was a retrospective cohort study of singleton gestations with an antenatal diagnosis of gastroschisis seen in our ultrasound unit from 2001 to 2010. We reviewed stored images from the last ultrasound examination before delivery, blinded to postnatal diagnoses and outcomes. Fetal intra‐ and extra‐abdominal bowel dilation (IABD and EABD, respectively) and bowel‐wall thickness were measured. Previously published definitions of bowel dilation, including > 6, > 10, > 14 and > 18 mm, were evaluated for association with the primary outcome of bowel atresia. The optimal threshold to define fetal bowel dilation was determined by evaluating the significance of association as well as test performance characteristics.Results: Of 109 consecutive patients with fetal gastroschisis, there were four cases of intrauterine fetal demise and three neonatal deaths. Of the 94 live births with complete outcome data, 39 (41.5%) had measurable IABD. There were 14 (14.9%) cases of bowel atresia. Using a threshold of > 14 mm, IABD was significantly associated with an increased risk for bowel atresia (relative risk, 3.1 (95% CI, 1.2–8.2)) with a sensitivity of 57.1%, specificity of 75.0%, positive predictive value of 28.6% and negative predictive value of 90.9%. IABD > 14 mm was also associated with a significantly longer stay in neonatal intensive care unit. There was no significant association between EABD and bowel atresia at any of the thresholds evaluated.Conclusion: IABD > 14 mm is associated with an increased risk for postnatal bowel atresia in fetal gastroschisis. This finding may be useful in counseling patients regarding the anticipated postnatal course for their neonate. Copyright © 2013 ISUOG. Published by John Wiley & Sons Ltd.
- 5 June 2013
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 27 (1) , 89-93
Clinical accuracy of estimated fetal weight in term pregnancies in a teaching hospital
Objective: To evaluate whether clinical characteristics alter the accuracy of clinical estimation of fetal weight (EFW) in term pregnancies in a teaching hospital. Methods: Secondary analysis of a retrospective cohort study of patients presenting for labor at term. Clinical EFW was performed using Leopold maneuvers. A Spearman’s rank correlation coefficient (r) was used to evaluate the linear relationship between clinical EFW and actual birth weight (BW). Body mass index (BMI), gestational age, fetal station, and admission diagnosis were evaluated with respect to their impact on clinical EFW. The primary outcome was an absolute error between clinical EFW and actual BW >500 g. Results: Of 3797 patients, 941 (24.8%) had an absolute error in clinical EFW exceeding 500 g. The overall correlation between clinical EFW and actual BW was weak (r = 0.4). There was a significant trend of improved accuracy of clinical EFW with increasing gestational age; however, BMI, fetal station, and admission diagnosis did not have significant effects. Of 221 cases of macrosomia (>4000 g), 181 (81.9%) were undetected by clinical EFW. Conclusion: The correlation between clinical EFW and actual BW is overall weak, particularly in patients with macrosomic fetuses; however, BMI, admission diagnosis, and fetal station do not have a significant impact.
- 5 June 2013
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 27 (1) , 89-93
Clinical accuracy of estimated fetal weight in term pregnancies in a teaching hospital
Objective: To evaluate whether clinical characteristics alter the accuracy of clinical estimation of fetal weight (EFW) in term pregnancies in a teaching hospital. Methods: Secondary analysis of a retrospective cohort study of patients presenting for labor at term. Clinical EFW was performed using Leopold maneuvers. A Spearman’s rank correlation coefficient (r) was used to evaluate the linear relationship between clinical EFW and actual birth weight (BW). Body mass index (BMI), gestational age, fetal station, and admission diagnosis were evaluated with respect to their impact on clinical EFW. The primary outcome was an absolute error between clinical EFW and actual BW >500 g. Results: Of 3797 patients, 941 (24.8%) had an absolute error in clinical EFW exceeding 500 g. The overall correlation between clinical EFW and actual BW was weak (r = 0.4). There was a significant trend of improved accuracy of clinical EFW with increasing gestational age; however, BMI, fetal station, and admission diagnosis did not have significant effects. Of 221 cases of macrosomia (>4000 g), 181 (81.9%) were undetected by clinical EFW. Conclusion: The correlation between clinical EFW and actual BW is overall weak, particularly in patients with macrosomic fetuses; however, BMI, admission diagnosis, and fetal station do not have a significant impact.
- Open Access
- 1 December 2012
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 31 (12) , 1935-1941
Isolated Short Femur Length on Second-Trimester Sonography
Objectives To estimate the association between isolated second‐trimester short femur length and fetal growth restriction as well as other adverse perinatal outcomes. Methods We conducted a retrosp...
- 1 December 2012
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 31 (12) , 1935-1941
Open AccessIsolated Short Femur Length on Second-Trimester Sonography
Objectives To estimate the association between isolated second‐trimester short femur length and fetal growth restriction as well as other adverse perinatal outcomes. Methods We conducted a retrosp...
- Open Access
- 18 October 2012
- Published by Springer Nature in Journal of Perinatology
- Vol. 33 (5) , 352-357
Screening for fetal growth disorders by clinical exam in the era of obesity
Objective: To evaluate the performance of clinical estimation of fetal weight as a screening test for fetal growth disorders and then to estimate the effect of maternal body mass index (BMI) on its screening efficiency. Study Design: This was a retrospective cohort study of patients referred for third trimester ultrasound for the indication of ‘size unequal to dates’. Patients with medical co-morbidities that may alter their a priori risk for fetal growth disorders were excluded. The incidence of fetal growth disorders as well as amniotic fluid disturbances was determined for each group and then compared across maternal BMI categories of −2, 25–30 kg m−2, ⩾30 kg m−2 and ⩾40 kg m−2. To evaluate the accuracy of clinical estimation of fetal weight in predicting fetal growth disorders, the sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratios, as well as number needed to scan (NNS) was calculated and compared across BMI categories. Result: Of 51 366 patients, 1623 were referred for the indication of size>dates and 1543 for the indication of size90th percentile and 13.5 and 96.7% for predicting BW<10th percentile. The NNS to detect one neonate with a BW90th percentile ranged from 6 to 13 across BMI categories. Conclusion: Overall, clinical estimation of fetal weight yields a low detection rate of fetal growth abnormalities; however, its screening efficiency is not adversely impacted by maternal BMI.
- 18 October 2012
- Published by Springer Nature in Journal of Perinatology
- Vol. 33 (5) , 352-357
Open AccessScreening for fetal growth disorders by clinical exam in the era of obesity
Objective: To evaluate the performance of clinical estimation of fetal weight as a screening test for fetal growth disorders and then to estimate the effect of maternal body mass index (BMI) on its screening efficiency. Study Design: This was a retrospective cohort study of patients referred for third trimester ultrasound for the indication of ‘size unequal to dates’. Patients with medical co-morbidities that may alter their a priori risk for fetal growth disorders were excluded. The incidence of fetal growth disorders as well as amniotic fluid disturbances was determined for each group and then compared across maternal BMI categories of −2, 25–30 kg m−2, ⩾30 kg m−2 and ⩾40 kg m−2. To evaluate the accuracy of clinical estimation of fetal weight in predicting fetal growth disorders, the sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratios, as well as number needed to scan (NNS) was calculated and compared across BMI categories. Result: Of 51 366 patients, 1623 were referred for the indication of size>dates and 1543 for the indication of size90th percentile and 13.5 and 96.7% for predicting BW<10th percentile. The NNS to detect one neonate with a BW90th percentile ranged from 6 to 13 across BMI categories. Conclusion: Overall, clinical estimation of fetal weight yields a low detection rate of fetal growth abnormalities; however, its screening efficiency is not adversely impacted by maternal BMI.
- 31 July 2012
- Published by Wiley in Prenatal Diagnosis
- Vol. 32 (10) , 1002-1007
First‐trimester prediction of preterm birth using ADAM12, PAPP‐A, uterine artery Doppler, and maternal characteristics
Objective: The objective of this study was to estimate the efficiency of first‐trimester a disintegrin and metalloprotease 12 (ADAM12), pregnancy‐associated plasma protein A (PAPP‐A), uterine artery Doppler, and maternal characteristics in the prediction of preterm birth (PTB).Methods: This was a prospective cohort study of patients presenting for first‐trimester aneuploidy screening. Maternal serum ADAM12 and PAPP‐A levels were measured by immunoassay, and mean uterine artery Doppler pulsatility indices were calculated. The primary outcome was PTB <34 weeks' gestation, and the secondary outcome was PTB <37 weeks' gestation. Logistic regression was used to model the prediction of PTB using ADAM12, PAPP‐A, uterine artery Doppler, and maternal characteristics, individually and in combination. Sensitivity, specificity, and area under the receiver‐operating characteristic curves were compared between models.Results: Of 578 patients, 36 (6.2%) delivered <34 weeks, and 78 (13.5%) delivered <37 weeks. For a 20% fixed false positive rate, ADAM12, PAPP‐A, and uterine artery Doppler identified 58%, 52%, and 62% of patients with PTB <34 weeks and 42%, 48%, and 50% of patients with PTB <37 weeks, respectively. Combining these first‐trimester parameters did not improve the predictive efficiency of the models.Conclusion: First‐trimester ADAM12, PAPP‐A, and uterine artery Doppler are each modestly predictive of PTB; however, combinations of these parameters do not further improve their screening efficiency. © 2012 John Wiley & Sons, Ltd.
- 31 July 2012
- Published by Wiley in Prenatal Diagnosis
- Vol. 32 (10) , 1002-1007
First‐trimester prediction of preterm birth using ADAM12, PAPP‐A, uterine artery Doppler, and maternal characteristics
Objective: The objective of this study was to estimate the efficiency of first‐trimester a disintegrin and metalloprotease 12 (ADAM12), pregnancy‐associated plasma protein A (PAPP‐A), uterine artery Doppler, and maternal characteristics in the prediction of preterm birth (PTB).Methods: This was a prospective cohort study of patients presenting for first‐trimester aneuploidy screening. Maternal serum ADAM12 and PAPP‐A levels were measured by immunoassay, and mean uterine artery Doppler pulsatility indices were calculated. The primary outcome was PTB <34 weeks' gestation, and the secondary outcome was PTB <37 weeks' gestation. Logistic regression was used to model the prediction of PTB using ADAM12, PAPP‐A, uterine artery Doppler, and maternal characteristics, individually and in combination. Sensitivity, specificity, and area under the receiver‐operating characteristic curves were compared between models.Results: Of 578 patients, 36 (6.2%) delivered <34 weeks, and 78 (13.5%) delivered <37 weeks. For a 20% fixed false positive rate, ADAM12, PAPP‐A, and uterine artery Doppler identified 58%, 52%, and 62% of patients with PTB <34 weeks and 42%, 48%, and 50% of patients with PTB <37 weeks, respectively. Combining these first‐trimester parameters did not improve the predictive efficiency of the models.Conclusion: First‐trimester ADAM12, PAPP‐A, and uterine artery Doppler are each modestly predictive of PTB; however, combinations of these parameters do not further improve their screening efficiency. © 2012 John Wiley & Sons, Ltd.
- 1 November 2011
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 118 (5) , 1137-1144
Effect of Regional Anesthesia on the Success Rate of External Cephalic Version
OBJECTIVE: To estimate whether the use of regional anesthesia is associated with increased success of external cephalic version. DATA SOURCES: We searched MEDLINE, EMBASE, the Cochrane Library, and clinical trial registries. METHODS OF STUDY SELECTION: Electronic databases were searched from 1966 through April 2011 for published, randomized controlled trials in the English language comparing regional anesthesia with no regional anesthesia for external cephalic version. The primary outcome was external cephalic version success. Secondary outcomes included cesarean delivery, maternal discomfort, and adverse events. Pooled risk ratios (relative risk) were calculated using a random-effects model. Heterogeneity was assessed using the Cochran's Q statistic and quantified using the I2 method. TABULATION, INTEGRATION, AND RESULTS: Six randomized controlled trials met criteria for study inclusion. Regional anesthesia was associated with a higher external cephalic version success rate compared with intravenous or no analgesia (59.7% compared with 37.6%; pooled relative risk 1.58; 95% confidence interval [CI] 1.29–1.93). This significant association persisted when the data were stratified by type of regional anesthesia (spinal compared with epidural). The number needed to treat with regional anesthesia to achieve one additional successful external cephalic version was five. There was no evidence of statistical heterogeneity (P=.32, I2=14.9%) or publication bias (Harbord test P=.78). There was no statistically significant difference in the risk of cesarean delivery comparing regional anesthesia with intravenous or no analgesia (48.4% compared with 59.3%; pooled relative risk 0.80; 95% CI 0.55–1.17). Adverse events were rare and not significantly different between the two groups. CONCLUSION: Regional anesthesia is associated with a higher success rate of external cephalic version.
- 1 November 2011
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 118 (5) , 1137-1144
Effect of Regional Anesthesia on the Success Rate of External Cephalic Version
OBJECTIVE: To estimate whether the use of regional anesthesia is associated with increased success of external cephalic version. DATA SOURCES: We searched MEDLINE, EMBASE, the Cochrane Library, and clinical trial registries. METHODS OF STUDY SELECTION: Electronic databases were searched from 1966 through April 2011 for published, randomized controlled trials in the English language comparing regional anesthesia with no regional anesthesia for external cephalic version. The primary outcome was external cephalic version success. Secondary outcomes included cesarean delivery, maternal discomfort, and adverse events. Pooled risk ratios (relative risk) were calculated using a random-effects model. Heterogeneity was assessed using the Cochran's Q statistic and quantified using the I2 method. TABULATION, INTEGRATION, AND RESULTS: Six randomized controlled trials met criteria for study inclusion. Regional anesthesia was associated with a higher external cephalic version success rate compared with intravenous or no analgesia (59.7% compared with 37.6%; pooled relative risk 1.58; 95% confidence interval [CI] 1.29–1.93). This significant association persisted when the data were stratified by type of regional anesthesia (spinal compared with epidural). The number needed to treat with regional anesthesia to achieve one additional successful external cephalic version was five. There was no evidence of statistical heterogeneity (P=.32, I2=14.9%) or publication bias (Harbord test P=.78). There was no statistically significant difference in the risk of cesarean delivery comparing regional anesthesia with intravenous or no analgesia (48.4% compared with 59.3%; pooled relative risk 0.80; 95% CI 0.55–1.17). Adverse events were rare and not significantly different between the two groups. CONCLUSION: Regional anesthesia is associated with a higher success rate of external cephalic version.
- 22 July 2011
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 29 (03) , 153-158
The Relationship between Maternal Body Mass Index and Tobacco Use on Small-for-Gestational-Age Infants
We sought to estimate the association between prepregnancy body mass index (BMI) and small-for-gestational-age (SGA) neonates and to determine if there is a synergistic effect of tobacco use on SGA across all BMI strata. We performed a retrospective cohort study of 65,104 patients seen for second-trimester ultrasound. BMI was categorized into underweight, normal weight, overweight, and obese. SGA was defined as birth weight <10th percentile and <5th percentile. Univariable and multivariable logistic regression analyses were used to evaluate the association between BMI and SGA. Stratified analyses and tests for effect modification were performed to evaluate for a potential synergistic effect between tobacco use and abnormal prepregnancy BMI on SGA. After controlling for potential confounders, underweight BMI was associated with an increased risk for SGA <10th percentile (adjusted odds ratio [aOR] 1.8, 95% confidence interval [CI] 1.5 to 2.1), while overweight (aOR 0.7, 95% CI 0.7 to 0.8) and obese BMIs (aOR 0.6, 95% CI 0.5 to 0.7) were associated with a decreased risk of SGA. There was no effect modification of tobacco use on the risk of SGA across all BMI categories. Although both tobacco and underweight BMI are independently associated with SGA, there was no evidence of synergism. Continued emphasis on both smoking cessation and maintenance of normal prepregnancy BMI remains paramount to decreasing the incidence of SGA.
- 22 July 2011
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 29 (03) , 153-158
The Relationship between Maternal Body Mass Index and Tobacco Use on Small-for-Gestational-Age Infants
We sought to estimate the association between prepregnancy body mass index (BMI) and small-for-gestational-age (SGA) neonates and to determine if there is a synergistic effect of tobacco use on SGA across all BMI strata. We performed a retrospective cohort study of 65,104 patients seen for second-trimester ultrasound. BMI was categorized into underweight, normal weight, overweight, and obese. SGA was defined as birth weight <10th percentile and <5th percentile. Univariable and multivariable logistic regression analyses were used to evaluate the association between BMI and SGA. Stratified analyses and tests for effect modification were performed to evaluate for a potential synergistic effect between tobacco use and abnormal prepregnancy BMI on SGA. After controlling for potential confounders, underweight BMI was associated with an increased risk for SGA <10th percentile (adjusted odds ratio [aOR] 1.8, 95% confidence interval [CI] 1.5 to 2.1), while overweight (aOR 0.7, 95% CI 0.7 to 0.8) and obese BMIs (aOR 0.6, 95% CI 0.5 to 0.7) were associated with a decreased risk of SGA. There was no effect modification of tobacco use on the risk of SGA across all BMI categories. Although both tobacco and underweight BMI are independently associated with SGA, there was no evidence of synergism. Continued emphasis on both smoking cessation and maintenance of normal prepregnancy BMI remains paramount to decreasing the incidence of SGA.
- 1 June 2011
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 117 (6) , 1341-1348
Echogenic Bowel on Second-Trimester Ultrasonography
OBJECTIVE: To estimate if echogenic bowel diagnosed on second-trimester ultrasonography has an independent risk association with intrauterine growth restriction (IUGR) and intrauterine fetal demise. METHODS: This is a retrospective cohort study of all patients with singleton gestations who presented to our institution for second-trimester ultrasonography between 1990 and 2008. Study groups were defined by the presence or absence of echogenic bowel. Primary outcomes were IUGR, defined as birth weight less than the 10th percentile for gestational age and intrauterine fetal demise at 20 weeks or more of gestation. Univariable and multivariable logistic regression analyses were used to estimate the risk of intrauterine fetal demise and IUGR in fetuses with echogenic bowel. Analyses were repeated after excluding cases of aneuploidy, cytomegalovirus (CMV) infection, other major congenital anomalies, and abnormal second-trimester serum screening results. RESULTS: Of 64,048 patients, the incidence of echogenic bowel was 0.4%. Of these, echogenic bowel was an isolated finding in 188 (72.3%) cases. There were 579 (0.9%) cases of intrauterine fetal demise and 8,173 (12.8%) cases of IUGR in the entire cohort. After excluding cases of aneuploidy and CMV infection, the incidence of intrauterine fetal demise was 7.3% in the echogenic bowel group compared with 0.9% in the nonechogenic bowel group, translating to an absolute risk increase of 6.4%. The incidence of IUGR in the echogenic bowel group was 19.5% compared with 12.9% in the nonechogenic bowel group (absolute risk increase, 6.6%). After controlling for potential confounders, echogenic bowel was significantly associated with both intrauterine fetal demise (adjusted odds ratio [OR] 9.6, 95% confidence interval [CI] 5.8–15.9) and IUGR (adjusted OR 2.1, 95% CI 1.5–2.9). This risk association remained significant even when evaluating echogenic bowel as an isolated sonographic finding. CONCLUSION: The presence of echogenic bowel on ultrasonography is independently associated with an increased risk for both IUGR and intrauterine fetal demise. Serial growth assessment and antenatal testing may be warranted in these patients. LEVEL OF EVIDENCE: II
- 1 June 2011
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 117 (6) , 1341-1348
Echogenic Bowel on Second-Trimester Ultrasonography
OBJECTIVE: To estimate if echogenic bowel diagnosed on second-trimester ultrasonography has an independent risk association with intrauterine growth restriction (IUGR) and intrauterine fetal demise. METHODS: This is a retrospective cohort study of all patients with singleton gestations who presented to our institution for second-trimester ultrasonography between 1990 and 2008. Study groups were defined by the presence or absence of echogenic bowel. Primary outcomes were IUGR, defined as birth weight less than the 10th percentile for gestational age and intrauterine fetal demise at 20 weeks or more of gestation. Univariable and multivariable logistic regression analyses were used to estimate the risk of intrauterine fetal demise and IUGR in fetuses with echogenic bowel. Analyses were repeated after excluding cases of aneuploidy, cytomegalovirus (CMV) infection, other major congenital anomalies, and abnormal second-trimester serum screening results. RESULTS: Of 64,048 patients, the incidence of echogenic bowel was 0.4%. Of these, echogenic bowel was an isolated finding in 188 (72.3%) cases. There were 579 (0.9%) cases of intrauterine fetal demise and 8,173 (12.8%) cases of IUGR in the entire cohort. After excluding cases of aneuploidy and CMV infection, the incidence of intrauterine fetal demise was 7.3% in the echogenic bowel group compared with 0.9% in the nonechogenic bowel group, translating to an absolute risk increase of 6.4%. The incidence of IUGR in the echogenic bowel group was 19.5% compared with 12.9% in the nonechogenic bowel group (absolute risk increase, 6.6%). After controlling for potential confounders, echogenic bowel was significantly associated with both intrauterine fetal demise (adjusted odds ratio [OR] 9.6, 95% confidence interval [CI] 5.8–15.9) and IUGR (adjusted OR 2.1, 95% CI 1.5–2.9). This risk association remained significant even when evaluating echogenic bowel as an isolated sonographic finding. CONCLUSION: The presence of echogenic bowel on ultrasonography is independently associated with an increased risk for both IUGR and intrauterine fetal demise. Serial growth assessment and antenatal testing may be warranted in these patients. LEVEL OF EVIDENCE: II